Reasonable precis of some of my work
You omitted another relevant bit though
The TRANSFORM screening RCT (that I am Chief Investigator for) in which focal therapy is mandated in the screening arms (n=150-300K) (£60M from
@ProstateUK & UK National Institute for Health Research
Fantastic news! Please correct me if I’m wrong or missing anything as I wish to have a good understanding of the RCTs in this space
IP4-CHRONOS-A
Focal HIFU/cryo vs surgery/RT
Closed after pilot failed its feasibility criterion
IP17-APOLLO
Focal therapy ± 3 months neoadjuvant apalutamide
Does not establish focal therapy vs radical therapy
CHRONOS-B
Focal therapy alone vs focal + short neoadjuvant hormonal manipulation
Closed pilot. Feasible, but again not FT vs standard definitive treatment
IP2-ATLANTA
In de novo mHSPC: SOC vs ablative prostate treatment vs radical local therapy, with MDT strategies
Fascinating, but this is cytoreduction in metastatic disease, not a test of focal therapy as definitive localized therapy
PART
Partial ablation vs radical treatment
The most important UK RCT, but Ahmed is not the chief investigator
For partial ablation, the current protocol can allow a repeat focal ablation before declaring failure.
So, is there an RCT he is running that compares FT to definitive treatment?
Very interested to learn more if so or be corrected if I’m off the mark.
Thanks in advance and for all of the hard work!